PE20000556A1 - Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla - Google Patents

Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla

Info

Publication number
PE20000556A1
PE20000556A1 PE1999000407A PE00040799A PE20000556A1 PE 20000556 A1 PE20000556 A1 PE 20000556A1 PE 1999000407 A PE1999000407 A PE 1999000407A PE 00040799 A PE00040799 A PE 00040799A PE 20000556 A1 PE20000556 A1 PE 20000556A1
Authority
PE
Peru
Prior art keywords
acid
phenyl
cycloalkylidene
cycloalkenyl
cycloalkyl
Prior art date
Application number
PE1999000407A
Other languages
English (en)
Inventor
Akira Aomatsu
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20000556(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20000556A1 publication Critical patent/PE20000556A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymerisation Methods In General (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)UN DERIVADO DEL ACIDO 4-AMINO-3-SUSTITUIDO-BUTANOICO DE FORMULA I; R1 ES H, OH, METILO, ETILO; R2 ES ALQUILO C3-C8, ALQUILENO C3-C8, CICLOALQUILO C3-C8, ANILLO CONDENSADO POR ORTOFUSION DE FENILO CON CICLOALQUILO C4-C8 O CON CICLOALQUENILO C5-C8, O CON CILOALCANODIENILO; CICLOALQUILO C5-C8, CICLOALQUENILO C5-C8, FENILO, NAFTILO, ALQUILFENILO, ALQUILO-O-, FENILO-O-, DIFENILAMINO O R1 Y R2 FORMAN UN CICLOALQUILIDENO C5-C8, CICLOALQUENILIDENO C5-C8, ANILLO FORMADO POR ORTOFUSION DE FENILO Y CICLOALQUILIDENO C4-C8, CICLOALQUENILIDENO C5-C8, ENTRE OTROS; EL FENILO ES OPCIONALMENTE SUSTITUIDO CON HALOGENO, TRIFLUOROMETILO, b)UN ESTABILIZADOR DE LA COMPOSICION QUE ES UN O AMINOACIDO QUE PUEDE SER NEUTRAL, ACIDO, BASICO. LOS DERIVADOS SON DE PREFERENCIA GABAPENTINA, PREGABALINA, BACLOFENO, ACIDO 3-AMINOMETIL-4-CICLOHEXILO-BUTANOICO, ACIDO 3-AMINOMETIL-5-CICLOHEXIL-PENTANOICO, ACIDO 3-AMINOMETIL-4-FENILBUTANOICO, ACIDO 3-AMINOMETIL-5-FENIL-PENTANOICO. LA RELACION DE AMINOACIDO/DERIVADO DEL COMPUESTO ES 0,001 MOLES/MOL A 80 MOLES/MOL. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE EPILEPSIA, DESMAYOS, HIPOCINESIA, TRAUMAS CRANEALES, TRASTORNOS NEURODEGENERATIVOS, ENFERMEDAD DE ALZHEIMER
PE1999000407A 1998-05-15 1999-05-14 Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla PE20000556A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13311398 1998-05-15

Publications (1)

Publication Number Publication Date
PE20000556A1 true PE20000556A1 (es) 2000-08-10

Family

ID=15097118

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000407A PE20000556A1 (es) 1998-05-15 1999-05-14 Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla

Country Status (37)

Country Link
US (1) US7309719B1 (es)
EP (1) EP1077692B1 (es)
JP (1) JP4612923B2 (es)
KR (1) KR100602047B1 (es)
CN (1) CN1303991C (es)
AR (1) AR020323A1 (es)
AT (1) ATE271864T1 (es)
AU (1) AU768277B2 (es)
BR (1) BR9910508B1 (es)
CA (1) CA2327285C (es)
CO (1) CO5021224A1 (es)
CR (1) CR6026A (es)
CU (1) CU23253B7 (es)
DE (1) DE69918977T2 (es)
DK (1) DK1077692T3 (es)
EG (1) EG26803A (es)
ES (1) ES2221385T3 (es)
GT (1) GT199900069A (es)
HK (1) HK1036586A1 (es)
HN (1) HN1999000072A (es)
HU (1) HU228771B1 (es)
ID (1) ID27724A (es)
IL (2) IL139298A0 (es)
IS (1) IS2233B (es)
MY (1) MY157878A (es)
NO (1) NO328959B1 (es)
NZ (1) NZ508015A (es)
PA (1) PA8472801A1 (es)
PE (1) PE20000556A1 (es)
PL (1) PL204921B1 (es)
PT (1) PT1077692E (es)
SI (1) SI1077692T1 (es)
SV (1) SV1999000064A (es)
TW (1) TWI243054B (es)
UY (1) UY25512A1 (es)
WO (1) WO1999059573A1 (es)
ZA (1) ZA200006484B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
AU2001266992B8 (en) * 2000-06-16 2005-12-01 Teva Pharmaceutical Industries Ltd. Stable gabapentin having pH within a controlled range
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
WO2001097612A1 (en) * 2000-06-16 2001-12-27 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 2o ppm of chlorine ion
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
SK286227B6 (sk) * 2001-05-25 2008-05-06 Warner-Lambert Company Llc Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie
JP2007520547A (ja) * 2004-02-04 2007-07-26 アレムビック・リミテッド ベンラファキシン塩酸塩の徐放性コーティングされた小型錠剤
CA2565095A1 (en) * 2004-05-17 2005-12-08 William S. Brusilow Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007107835A2 (en) * 2006-03-17 2007-09-27 Aurobindo Pharma Limited Stable liquid formulations of antiepileptic agents
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
MX364974B (es) 2009-05-19 2019-05-16 Neuroderm Ltd Composiciones para la administracion continua de inhibidores de dopa descarboxilasa.
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
TR201005241A1 (tr) 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
ES2776734T3 (es) 2010-11-15 2020-07-31 Neuroderm Ltd Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello
CN104349768B (zh) 2012-06-05 2017-11-07 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
US20160338949A1 (en) 2014-01-28 2016-11-24 Sun Pharmaceutical Industries Limited Stabilized gastroretentive tablets of pregabalin
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
MX2016011837A (es) 2014-03-13 2017-04-27 Neuroderm Ltd Composiciones de inhibidores de la dopa decarboxilasa.
EP2923694B1 (en) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
EP2929878A1 (en) * 2014-04-09 2015-10-14 Arven Ilac Sanayi ve Ticaret A.S. Extended release formulations of gabapentin
JP2018520112A (ja) 2015-05-26 2018-07-26 オディディ，イサ 制御持続放出プレガバリン
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
US20220016061A1 (en) 2018-10-04 2022-01-20 Medrx Co., Ltd. Preparation Stabilized by Means of Nonaqueous Solvent
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
AU2020370758A1 (en) 2019-10-25 2022-06-02 Kyoto University Preventative or therapeutic agent for tauopathy
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
CN112843015A (zh) * 2021-04-08 2021-05-28 海南鑫开源医药科技有限公司 一种加巴喷丁胶囊制剂及其制备方法
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
GB8311804D0 (en) * 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
CA1249968A (en) 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
JPS63253022A (ja) 1987-04-08 1988-10-20 Nitto Electric Ind Co Ltd バクロフエン外用製剤
PH26730A (en) 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
HUT59656A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
JPH0597703A (ja) * 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
RU94046105A (ru) * 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5248678A (en) * 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
US5260337A (en) * 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
JP3467794B2 (ja) * 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JPH0867636A (ja) * 1994-08-30 1996-03-12 Yamanouchi Pharmaceut Co Ltd 播種性血管内凝固症候群（ｄｉｃ）の予防治療薬
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
JPH1017476A (ja) * 1996-06-28 1998-01-20 Nippon Seiyaku Kk 敗血症用非経口製剤及びそれによる予防及び治療方法
US6172041B1 (en) * 1996-07-22 2001-01-09 University Of Utah Research Foundation Use of conantokins
KR100491282B1 (ko) * 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
AU2002345664C1 (en) * 2001-06-11 2008-03-06 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof

Also Published As

Publication number Publication date
IS5666A (is) 2000-10-16
HUP0102022A3 (en) 2002-11-28
TWI243054B (en) 2005-11-11
AU4073599A (en) 1999-12-06
BR9910508A (pt) 2001-01-02
CU23253B7 (es) 2007-12-17
ID27724A (id) 2001-04-26
EP1077692B1 (en) 2004-07-28
HUP0102022A2 (hu) 2001-11-28
SI1077692T1 (en) 2004-10-31
HK1036586A1 (en) 2002-01-11
NO20005768D0 (no) 2000-11-14
JP2000034226A (ja) 2000-02-02
KR20010043611A (ko) 2001-05-25
JP4612923B2 (ja) 2011-01-12
SV1999000064A (es) 2000-03-31
HN1999000072A (es) 2000-06-05
CR6026A (es) 2008-08-26
NO20005768L (no) 2000-11-14
UY25512A1 (es) 1999-07-19
ZA200006484B (en) 2002-02-11
DE69918977D1 (de) 2004-09-02
DK1077692T3 (da) 2004-12-06
DE69918977T2 (de) 2005-07-28
US7309719B1 (en) 2007-12-18
CA2327285C (en) 2005-06-14
WO1999059573A1 (en) 1999-11-25
AU768277B2 (en) 2003-12-04
CN1303991C (zh) 2007-03-14
ATE271864T1 (de) 2004-08-15
WO1999059573A9 (en) 2000-05-04
NO328959B1 (no) 2010-06-28
PL204921B1 (pl) 2010-02-26
CN1301155A (zh) 2001-06-27
IL139298A0 (en) 2001-11-25
MY157878A (en) 2016-07-29
HU228771B1 (en) 2013-05-28
EP1077692A1 (en) 2001-02-28
EG26803A (en) 2014-09-21
NZ508015A (en) 2003-11-28
PA8472801A1 (es) 2001-12-14
PT1077692E (pt) 2004-12-31
KR100602047B1 (ko) 2006-07-19
PL344218A1 (en) 2001-10-08
IL139298A (en) 2009-07-20
IS2233B (is) 2007-04-15
GT199900069A (es) 2000-11-04
BR9910508B1 (pt) 2012-01-24
CA2327285A1 (en) 1999-11-25
CO5021224A1 (es) 2001-03-27
ES2221385T3 (es) 2004-12-16
AR020323A1 (es) 2002-05-08

Similar Documents

Publication Publication Date Title
PE20000556A1 (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla
DK0447285T3 (da) Nephtalenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem
KR890701559A (ko) 3-인돌피루브산 유도체 및 그의 제약 용도
AU2095092A (en) New arylethylamine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
NZ191867A (en) N1,n1,2,3,4,5,6-substituted-1-piperazine-carboxamides and carbothioamides
ES2071621T3 (es) Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
RU94030812A (ru) Производные фосфоноянтарной кислоты, способ их получения и содержащие эти соединения фармацевтические композиции
GT199900068A (es) Composiciones solidas que contienen gabapentina y proceso para su preparacion.
PT911331E (pt) Compostos de dibenzoxazepina substituidos composicoes farmaceuticas e metodos de utilizacao
AR014747A1 (es) Derivados de piperidina, un procedimiento para prepararlos, el empleo de los mismos para preparar un medicamento, una composicion farmaceutica que loscontiene y un procedimiento para obtener esta composicion farmaceutica
DK0472501T3 (da) Codeinsalt af en substitueret carboxylsyre, fremgangsmåde til dets fremstilling, dets anvendelse samt farmaceutiske præparater
RU94036749A (ru) Замещенные 1-нафтилпиразол-3-карбоксамиды, способ их получения, содержащие их фармацевтические композиции и промежуточные соединения синтеза
ES2162916T3 (es) Derivados de acido pirimidin- o triazincarboxilico para el empleo como medicamentos.
ES508587A0 (es) "procedimiento para la preparacion de nuevas amidas de acidos carboxilicos".
DE69209166D1 (de) Diclofenac-Cholinsalz, Verfahren zur Herstellung und pharmazeutische Zusammensetzungen, die es enthalten
ES2043351T3 (es) Preparado farmaceutico para el tratamiento de enfermedades hepaticas.
ES2058085T3 (es) Composicion anticonvulsivante que contiene un derivado de aminoacido, y utilizacion de dicho derivado de aminoacido.
EA199901012A1 (ru) Фармацевтические композиции на основе тизоксанида и нитазоксанида
DE69300453D1 (de) Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen.
DK1332764T3 (da) Mucoadhæsivt, termoresponsivt lægemiddel-bærer-præparat
PT99669A (pt) Processo para a preparacao de composicoes nematodicidas contendo como ingrediente activo 2r,5r-di-hidroximetil-3r,4r-di-hidroxipirrolidina (dmdp) como ingrediente activo
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
PT81314B (pt) Processo para a obtencao de derivados de tiadiazole activos sobre o sistema nervoso central

Legal Events

Date Code Title Description
FC Refusal